Patents by Inventor Jiro YASUDA

Jiro YASUDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19)
    Publication number: 20230190690
    Abstract: The present invention provides a therapeutic and/or preventive agent for coronavirus disease 2019 (COVID-19) comprising 5-aminolevulinic acid (ALA) or its derivative or a salt thereof and provides a method for treating and/or preventing coronavirus disease 2019 (COVID-19) using the therapeutic and/or preventive agent.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 22, 2023
    Applicants: NEOPHARMA JAPAN CO., LTD., NAGASAKI UNIVERSITY
    Inventors: Kiyoshi KITA, Kouichi MORITA, Jiro YASUDA, Yasuteru SAKURAI, Satofumi KAWATA, Tohru TANAKA, Motoyasu TOMIOKA, Kiyotaka FUJINE
  • PROPHYLACTIC OR THERAPEUTIC AGENT FOR RNA VIRUS-RELATED DISEASES
    Publication number: 20230147364
    Abstract: A a prophylactic or therapeutic agent for RNA virus-related diseases is provided, the prophylactic or therapeutic agent containing, as an active ingredient, at least one compound selected from the group consisting of a selective estrogen receptor modulator, an anti-tuberculosis drug, a CysLT1 receptor antagonist, a peroxisome proliferator-activated receptor ? (PPAR?) agonist, an arachidonate 5-lipoxygenase (5-LOX) inhibitor, a derivative thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: May 11, 2023
    Inventors: Haruhisa INOUE, Keiko IMAMURA, Jiro YASUDA, Yasuteru SAKURAI
  • Primer set for detecting SARS-CoV-2, method for testing SARS-CoV-2, and reagent and kit of testing SARS-CoV-2
    Patent number: 11345971
    Abstract: One embodiment according to the present invention relates to a primer set for detecting SARS-CoV-2, the set comprising a plurality of LAMP primers targeting one or more open reading frame (ORF) regions in a SARS-CoV-2 genome, wherein the one or more ORF regions are selected from the group consisting of Orf1b, OrfM, OrfN, and OrfS; and a technique relating to use of this primer set.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: May 31, 2022
    Assignees: NAGASAKI UNIVERSITY, CANON MEDICAL SYSTEMS CORPORATION
    Inventors: Jiro Yasuda, Rokusuke Yoshikawa, Haruka Abe
  • PRIMER SET FOR DETECTING SARS-COV-2, METHOD FOR TESTING SARS-COV-2, AND REAGENT AND KIT OF TESTING SARS-COV-2
    Publication number: 20220010389
    Abstract: One embodiment according to the present invention relates to a primer set for detecting SARS-CoV-2, the set comprising a plurality of LAMP primers targeting one or more open reading frame (ORF) regions in a SARS-CoV-2 genome, wherein the one or more ORF regions are selected from the group consisting of Orf1b, OrfM, OrfN, and OrfS; and a technique relating to use of this primer set.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 13, 2022
    Inventors: Jiro YASUDA, Rokusuke YOSHIKAWA, Haruka ABE
  • Primer set for detection of Zaire ebola virus, assay kit, and amplification method
    Patent number: 10563249
    Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: February 18, 2020
    Assignees: Nagasaki University, Canon Madical Systems Corporation
    Inventors: Jiro Yasuda, Yohei Kurosaki
  • PRIMER SET FOR DETECTION OF ZAIRE EBOLA VIRUS, ASSAY KIT, AND AMPLIFICATION METHOD
    Publication number: 20170369940
    Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 28, 2017
    Applicants: Nagasaki University, Toshiba Medical Systems Corporation
    Inventors: Jiro YASUDA, Yohei Kurosaki